Thinking of joining a study?

Register your interest

NCT04367883 | RECRUITING | COVID19


Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Sponsor:

Consorci Sanitari de Terrassa

Information provided by (Responsible Party):

Anna Puigdellívol-Sánchez

Brief Summary:

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Condition or disease

COVID19

Influenza Vaccination

ACE Inhibitors

ARB

Antihistamine Allergy

Amantadine

Intervention/treatment

Antihistamine

Amantadine

ACEI

ARB

Influenza vaccine and COVID

Detailed Description:

The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied. If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.

Study Type : OBSERVATIONAL
Estimated Enrollment : 3000 participants
Official Title : Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection
Actual Study Start Date : 2020-03-01
Estimated Primary Completion Date : 2025-01-19
Estimated Study Completion Date : 2028-02-24

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.
Exclusion Criteria
  • * None.
  • * For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Location Details

NCT04367883


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

Spain, Barcelona

Terrassa Hospital

terrace, Barcelona, Spain, 08227

Loading...